Why the study?
To evaluate the role of 18F-FDG PET/CT in assessing bone marrow involvement in rhabdomyosarcoma patients and whether it renders invasive bone marrow biopsy unnecessary.
Does 18F-FDG PET/CT accurately detect bone marrow involvement compared to bone marrow biopsy in pediatric rhabdomyosarcoma patients?
Does 18F-FDG PET/CT accurately detect bone marrow involvement compared to bone marrow biopsy in pediatric rhabdomyosarcoma patients?
18F-FDG PET/CT demonstrated 100% specificity and negative predictive value for detecting bone marrow metastasis in pediatric rhabdomyosarcoma, suggesting it may safely preclude the need for invasive bone marrow biopsy.
Answers are grounded in this paper and cite their sources.
May spare biopsy when negative in pediatric rhabdomyosarcoma; leaves open prospective validation before practice change.
Objectives: To evaluate role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/ CT) in assessing bone marrow involvement in rhabdomyosarcoma (RMS) patients, and whether 18F-FDG PET/CT findings render invasive bone marrow biopsy (BMB) unnecessary.
No takes yet. Share an insight, caveat, or question.
Pande et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: